Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Nuclea Biotechnologies, Inc.. (2/3/15). "Press Release: Nuclea Biotechnologies Inc. Partners with BacterioScan Inc. on Rapid Bacterial Detection and Quantification Diagnostic". Pittsfield, MA.

Organisations Organisation Nuclea Biotechnologies Inc.
  Organisation 2 BacterioScan Inc.
Products Product BacterioScan 216Dx instrument (laser microbial growth monitor)
  Product 2 diagnostic test, infection
Person Person Muraca, Patrick J. (Nuclea Biotechnologies 201309 CEO)

Nuclea Biotechnologies, Inc. announced today that it is partnering with BacterioScan™ Inc. (St. Louis, Missouri) in validation of their BacterioScan 216Dx instrument in a CLIA certified laboratory. This collaboration will focus on antimicrobial susceptibility testing (AST) to guide the best course of antibiotic treatment for different strains of urinary tract infections

BacterioScan™ is an in-vitro diagnostics (IVD) company headquartered in St. Louis which focuses on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan represents a new frontier in microbial lab technology that enables researchers to quantify bacterial concentration and growth in a liquid in under twenty minutes. Nuclea Biotechnologies, Inc. headquartered in Pittsfield, Massachusetts, is developing and commercializing molecular oncology and metabolic syndrome diagnostics, with a recent expansion into infectious diseases.

The BacterioScan 216Dx instrument is a Laser Microbial Growth Monitor used to detect and quantify bacterial concentrations that would typically fall below the detection limits of spectrophotometers and plate reader Optical Density (OD) measurements, potentially enabling more rapid selection of the right antibiotic treatment at the right dose. Today this instrument is at work in several world-class research hospitals and universities researching techniques for rapidly detecting antibiotic resistance and susceptibility in various types of bacterial infections. Initial work, including recent publications from the US Centers for Disease Control (CDC) and others, has indicated that the technology can reduce the time for selection of effective antibiotic therapy from 30+ hours to less than 3 hours, offering a potential breakthrough in addressing the worldwide urgent challenge of antibiotic resistance.

“We’re excited to be working with a great team at Nuclea Biotechnologies.” stated Dana Marshall, President and CEO of BacterioScan. He added “The deployment of our instrument in Nuclea’s CLIA labs provides us with the opportunity to build our core AST technology for a wide range of infectious disease diagnostic needs.”

“This agreement serves as a step forward for Nuclea’s endeavors in personalized medicine, as well as strengthens Nuclea’s position in the infectious disease marketplace,” said Patrick J Muraca, President and CEO of Nuclea Biotechnologies. “In a world of ever-growing antibiotic identification needs, Nuclea remains committed to equipping medical professionals with the tools to provide the right treatment for the right person.”

The BacterioScan instrument will be integrated within Nuclea’s CLIA laboratory in Pittsfield within the next three months.

Nuclea Biotechnologies, Inc. -- is headquartered in Pittsfield, Massachusetts with additional operations in Worcester and Cambridge, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung, and prostate cancer, as well as for diabetes and other metabolic syndromes. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries.

BacterioScan Inc. is an in-vitro diagnostics (IVD) company based in St. Louis, and focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan instruments can rapidly detect infection, classify the organism by type and size, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan is a privately held corporation, with operations in St Louis Missouri, and Israel.

Record changed: 2016-03-19


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Nuclea Biotechnologies Inc.

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

» top